A study published in the New England Journal of Medicine (NEJM) found that the presence of AR-V7, a variant of the androgen receptor, in circulating tumor cells from men with castration-resistant prostate cancer is associated with resistance to enzalutamide and abiraterone, two drugs used to treat advanced prostate cancer. The study enrolled 62 patients with metastatic castration-resistant prostate cancer, half of whom were treated with enzalutamide and the other half with abiraterone. AR-V7 was detected in 39% of enzalutamide-treated patients and 19% of abiraterone-treated patients. Patients with detectable AR-V7 had lower PSA response rates, shorter progression-free survival, and worse overall survival compared to those without AR-V7. The association between AR-V7 and resistance remained significant even after adjusting for full-length androgen receptor expression. AR-V7 is a truncated form of the androgen receptor that lacks the ligand-binding domain but remains active as a transcription factor. This variant may contribute to resistance to enzalutamide and abiraterone, which target the androgen receptor. The study suggests that AR-V7 could serve as a biomarker for resistance to these drugs. However, the clinical significance of AR-V7 in patients receiving these treatments remains to be fully validated in larger studies. The findings highlight the importance of understanding the mechanisms of resistance to these therapies and may help guide treatment decisions for patients with castration-resistant prostate cancer.A study published in the New England Journal of Medicine (NEJM) found that the presence of AR-V7, a variant of the androgen receptor, in circulating tumor cells from men with castration-resistant prostate cancer is associated with resistance to enzalutamide and abiraterone, two drugs used to treat advanced prostate cancer. The study enrolled 62 patients with metastatic castration-resistant prostate cancer, half of whom were treated with enzalutamide and the other half with abiraterone. AR-V7 was detected in 39% of enzalutamide-treated patients and 19% of abiraterone-treated patients. Patients with detectable AR-V7 had lower PSA response rates, shorter progression-free survival, and worse overall survival compared to those without AR-V7. The association between AR-V7 and resistance remained significant even after adjusting for full-length androgen receptor expression. AR-V7 is a truncated form of the androgen receptor that lacks the ligand-binding domain but remains active as a transcription factor. This variant may contribute to resistance to enzalutamide and abiraterone, which target the androgen receptor. The study suggests that AR-V7 could serve as a biomarker for resistance to these drugs. However, the clinical significance of AR-V7 in patients receiving these treatments remains to be fully validated in larger studies. The findings highlight the importance of understanding the mechanisms of resistance to these therapies and may help guide treatment decisions for patients with castration-resistant prostate cancer.